HMGB2 Mouse Monoclonal Antibody
- Known as:
- HMGB2 Mouse Monoclonal Antibody
- Catalog number:
- BIN-003148-M03
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- HMGB2 Mouse Monoclonal Antibody
Related genes to: HMGB2 Mouse Monoclonal Antibody
- Gene:
- HMGB2 NIH gene
- Name:
- high mobility group box 2
- Previous symbol:
- HMG2
- Synonyms:
- -
- Chromosome:
- 4q34.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-13
- Date modifiied:
- 2016-10-05
Related products to: HMGB2 Mouse Monoclonal Antibody
Related articles to: HMGB2 Mouse Monoclonal Antibody
- Recessive dystrophic epidermolysis bullosa is an inherited skin disorder characterized by fragile skin, blistering, and chronic wounds. Keratinocytes, the primary cells in the epidermis, are directly affected by persistent injury in recessive dystrophic epidermolysis bullosa, contributing to chronic inflammation. HMGB1 (high mobility group box 1) is elevated in the serum of individuals with recessive dystrophic epidermolysis bullosa. However, its role in keratinocyte inflammation remains unclear. In this study, we report an increase in expression in keratinocytes at chronic wound sites compared with that on matched nonwounded skin from an individual with recessive dystrophic epidermolysis bullosa, suggesting a potential link to the upregulation of local proinflammatory stimuli. Pharmacologic inhibition of HMGB1 using inflachromene reduced lipopolysaccharide-induced secretion of proinflammatory cytokines in keratinocytes, supporting a role for keratinocyte-specific HMGB1 in inflammatory response. Surprisingly, deletion of alone or together with its paralog did not suppress the release of proinflammatory cytokines in response to lipopolysaccharide. Furthermore, inflachromene still reduced the secretion of proinflammatory cytokines in - and -knockout cells. This unexpected discrepancy between genetic deletion and pharmacologic inhibition points to a more complex role for HMGB1 or off-target effects of the compound. These findings suggest that HMGB1 may contribute to proinflammatory signaling in keratinocytes; however, its exact function needs further investigation. - Source: PubMed
Publication date: 2026/05/12
Bui Kacey GuentherChang Ya-ChuChiraphapphaiboon WannasiriWang JianfengEbens Christen LTolar JakubBielinsky Anja-KatrinNguyen Hai Dang - Sensitive skin is characterized by hypersensitivity to normal stimuli, and objective diagnostic tools and treatments are still limited. Currently, cosmetics for sensitive skin are developed through the exclusion of known irritants rather than investigation into the underlying mechanisms of sensitivity. In this study, we developed an integrated pipeline combining transcriptome analysis via microneedle-based skin sampling (MISSM), bioinformatics, in vitro validation, and clinical assessment to identify sensitive skin-associated inflammatory biomarkers and cosmetic ingredients that regulate them. Candidate biomarkers and matched cosmetic ingredients were identified from transcriptomic data and validated in lactic acid-stimulated HaCaT and human dermal fibroblasts via qRT-PCR. A prototype emulsion was developed and evaluated in a 4-week open-label pilot clinical trial with longitudinal molecular monitoring via MISSM. After lactic acid stimulation, sensitive skin-associated biomarkers (, , , , and ) were significantly upregulated in both cell types, and cosmetic ingredients that regulate these biomarkers were confirmed in vitro. The emulsion prototype demonstrated hypoallergenicity in a primary irritation test. In the pilot clinical trial, target biomarker expression was significantly reduced in MISSM-derived samples, with improvements in skin hydration, barrier function, redness, and sensory reactivity also observed. This integrated pipeline will enable the discovery of inflammatory biomarker-regulating cosmetic ingredients, with potential applicability to various inflammatory skin conditions. - Source: PubMed
Publication date: 2026/06/09
Kim Seo HyeongKim Ji HyeShin Ji MinChoi Yoon MiKim Da SomSeo Su MinJang Eun YoungLee Sung JaeLim Jin-MukHan MinsooJeong Do HyeonLee Kwang Hoon - High-mobility group (HMG) protein families are critical regulators of chromatin structure and gene expression in breast cancer. This study systematically evaluates their expression patterns, genetic interactions, and clinical relevance. - Source: PubMed
Shariff Ehtesham AhmedAzharuddin AhmedAbu-Zaid RatebAl-Wathinani AhmedAlenazy Eid BasheerSharieff Raiyan Ehtesham Ahmed - Parapneumonic effusion (PPE) exacerbation is associated with high morbidity and mortality in pneumonia patients. However, the molecular signatures underlying the progression and severity of PPE remain poorly understood. We therefore employed whole-transcriptome profiling to comprehensively characterize the molecular landscape associated with PPE exacerbation and its clinical manifestations. - Source: PubMed
Publication date: 2026/06/12
Wu Kuo-AnChen MinWu Kun-LinLai Chih-HoChang Ian Yi-FengJan Fei-WenChin Chia-YinTasi Pei-ChuWu Chih-ChingKuo Yu-HsuanShih Li-JaneWang Wan-LingKao Yung-HsiYang Chia-Yu - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. Although standard immunochemotherapy is available, 30%-40% of patients develop refractory or relapsed disease, underscoring the need to elucidate the underlying mechanisms of therapy resistance. High mobility group box 2 (HMGB2) is overexpressed in DLBCL; however, its role in the pathogenesis of DLBCL and in mediating therapy resistance remains unclear. - Source: PubMed
Publication date: 2026/06/10
He SanxiuLiu YiTang YifengZhai LiuyueLuo XinZhao MingyuXiao QingXie XiaoqinFu HuihuiLi JunLi YaShu XuejiaoYang ZailinLiu YaoZhang Xiaomei